Drug Trial Radar · NCT06289166
Safety and Efficacy of STSP-0601 in Adult Patients with Hemophilia a or B with Inhibitor
Last checked: Nov 19, 2026Latest source record: Jan 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
25
Actual
Start
Mar 18, 2024
Primary completion
Oct 17, 2024
Study completion Oct 17, 2024
Sponsor
- Lead sponsor
- Staidson (Beijing) Biopharmaceuticals Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Mar 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the safety and efficacy of multiple-dose of STSP-0601 for the treatment of bleeding episodes in hemophilia A or B patients with inhibitor.
Conditions
- Hemophilia
Interventions
STSP-0601 for InjectionDrug
A Multiple-dose Design to Evaluate the Safety, Tolerability and Efficacy of STSP-0601 for Injection in hemophilia A or B patients with inhibitor.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of successfully treated bleeding episodesTime frame: 12 hours after first administration of study drug
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
Anhui Provincial Hospital
Hefei, Anhui, China
The Second Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China
Fujian Medical University Affiliated Union Medical College Hospital
Fuzhou, Fujian, China
Lanzhou University First Hospital
Lanzhou, Gansu, China
Southern Medical University Southern Hospital
Guangzhou, Guangdong, China
Shenzhen Second People's Hospital
Shenzhen, Guangdong, China
Guizhou Medical University Affiliated Hospital
Guiyang, Guizhou, China
Harbin First Hospital Hematology Tumor Research Center
Harbin, Heilongjiang, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Xiangya Hospital of Central South University
Changsha, Hunan, China
Nanjing University School of Medicine Affiliated Gulou Hospital
Nanjing, Jiangsu, China
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
The first hospital of Jilin University
Changchun, Jilin, China
Shengjing Hospital Affiliated to China Medical University
Shenyang, Liaoning, China
Affiliated Hospital of Qingdao University
Qingdao, Shandong, China
Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China
Xi'an Central Hospital
Xi’an, Shanxi, China
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Hospital of Hematology, Chinese Academy of Medical Sciences
Tianjin, Tianjin Municipality, China
The Second Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.